EA201291040A1 - Использование скорости увеличения желудочков при лечении болезни альцгеймера внутривенным иммуноглобулином - Google Patents

Использование скорости увеличения желудочков при лечении болезни альцгеймера внутривенным иммуноглобулином

Info

Publication number
EA201291040A1
EA201291040A1 EA201291040A EA201291040A EA201291040A1 EA 201291040 A1 EA201291040 A1 EA 201291040A1 EA 201291040 A EA201291040 A EA 201291040A EA 201291040 A EA201291040 A EA 201291040A EA 201291040 A1 EA201291040 A1 EA 201291040A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
treatment
alcehemer
increase during
intravenous immunoglobulin
Prior art date
Application number
EA201291040A
Other languages
English (en)
Inventor
Норман Р. Релкин
Original Assignee
Бакстер Интернэшнл Инк.
Бакстер Хелткэр С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44761427&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201291040(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бакстер Интернэшнл Инк., Бакстер Хелткэр С.А. filed Critical Бакстер Интернэшнл Инк.
Publication of EA201291040A1 publication Critical patent/EA201291040A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Disabilities (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

Изобретение относится к применению контроля методом МРТ скорости увеличения желудочков в качестве объективного показателя с целью оценки прогрессирования заболевания пациентов, страдающих болезнью Альцгеймера, и с целью определения эффективности лечения для режима лечения для пациентов с болезнью Альцгеймера. Предложены способы лечения болезни Альцгеймера и контроля эффективности лечения.
EA201291040A 2010-04-13 2011-04-13 Использование скорости увеличения желудочков при лечении болезни альцгеймера внутривенным иммуноглобулином EA201291040A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32373910P 2010-04-13 2010-04-13
PCT/US2011/032232 WO2011130355A1 (en) 2010-04-13 2011-04-13 Use of ventricular enlargement rate in intravenous immunoglobulin treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
EA201291040A1 true EA201291040A1 (ru) 2013-04-30

Family

ID=44761427

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291040A EA201291040A1 (ru) 2010-04-13 2011-04-13 Использование скорости увеличения желудочков при лечении болезни альцгеймера внутривенным иммуноглобулином

Country Status (17)

Country Link
US (2) US8066993B2 (ru)
EP (1) EP2451348A4 (ru)
JP (2) JP2013509985A (ru)
KR (1) KR20130114563A (ru)
CN (1) CN102946799A (ru)
AR (1) AR081534A1 (ru)
AU (1) AU2011240556B2 (ru)
BR (1) BR112012026224A2 (ru)
CA (1) CA2795651A1 (ru)
CL (1) CL2012002852A1 (ru)
CO (1) CO6592030A2 (ru)
EA (1) EA201291040A1 (ru)
IL (1) IL222245A0 (ru)
MX (1) MX2012011924A (ru)
SG (1) SG184820A1 (ru)
TW (1) TW201138807A (ru)
WO (1) WO2011130355A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280114A1 (en) * 2002-04-12 2009-11-12 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
EP2742855A1 (en) * 2012-12-11 2014-06-18 Friedrich-Alexander-Universität Erlangen-Nürnberg Brain functional magnetic resonance activity is associated with response to tumor necrosis factor inhibition
AU2014262890B2 (en) * 2013-05-06 2019-01-31 Takeda Pharmaceutical Company Limited Treatment of Alzheimer's disease subpopulations with pooled immunoglobulin G
KR20160111039A (ko) * 2014-02-08 2016-09-23 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
JP6548615B2 (ja) * 2016-08-23 2019-07-24 富士フイルム株式会社 磁場歪み算出装置、方法およびプログラム
CN108830830A (zh) * 2018-05-11 2018-11-16 深圳博脑医疗科技有限公司 一种脑萎缩程度的定量检测方法、检测装置及终端设备
KR102276545B1 (ko) * 2019-09-05 2021-07-15 고려대학교 산학협력단 Ct 영상 기반 부위별 대뇌 피질 수축율 예측 방법 및 장치

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064395A1 (fr) * 2002-01-31 2003-08-07 President Of National Center Of Neurology And Psychiatry Agents preventifs et therapeutiques destines a lutter contre des maladies neurodegeneratives
JP2008519282A (ja) * 2004-11-05 2008-06-05 ワイス アルツハイマー病治療薬をスクリーニングするための画像診断モダリティー
PT2182983E (pt) * 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
WO2009021708A2 (en) * 2007-08-13 2009-02-19 Baxter International Inc. Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe

Also Published As

Publication number Publication date
JP2012210413A (ja) 2012-11-01
BR112012026224A2 (pt) 2016-07-12
MX2012011924A (es) 2013-03-05
WO2011130355A1 (en) 2011-10-20
KR20130114563A (ko) 2013-10-17
CA2795651A1 (en) 2011-10-20
US20110251479A1 (en) 2011-10-13
EP2451348A4 (en) 2013-07-31
TW201138807A (en) 2011-11-16
IL222245A0 (en) 2012-12-31
AU2011240556B2 (en) 2012-06-21
AU2011240556A1 (en) 2012-04-19
CO6592030A2 (es) 2013-01-02
SG184820A1 (en) 2012-11-29
AR081534A1 (es) 2012-10-03
CL2012002852A1 (es) 2013-04-05
US20120071747A1 (en) 2012-03-22
US8066993B2 (en) 2011-11-29
JP2013509985A (ja) 2013-03-21
US8722042B2 (en) 2014-05-13
EP2451348A1 (en) 2012-05-16
CN102946799A (zh) 2013-02-27

Similar Documents

Publication Publication Date Title
EA201291040A1 (ru) Использование скорости увеличения желудочков при лечении болезни альцгеймера внутривенным иммуноглобулином
CA2941917C (en) Methods for the diagnosis and treatment of inflammatory bowel disease
MY164579A (en) Safe and functional humanized antibodies
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
BR112013017745A2 (pt) métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho
MX338421B (es) Anticuerpos fosfoespecificos que reconocen la proteina tau.
MX2016001186A (es) Diagnostico y terapia de cancer que implica celulas madre cancerosas.
MX356800B (es) Anticuerpo tau humanizado.
WO2013192274A3 (en) Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
EP3498729A3 (en) Therapeutic targets for alzheimer's disease
WO2012142301A3 (en) Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
EA201490883A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛА К α-СИНУКЛЕИНУ ДЛЯ ДИАГНОСТИКИ ПОВЫШЕННОГО УРОВНЯ α-СИНУКЛЕИНА В МОЗГЕ
BR112014029301A2 (pt) métodos de tratamento de síndrome metabólica através de modulação da proteína choque térmico (hsp) 90-beta
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
AU2012313353A8 (en) Screening method
FR2979346B1 (fr) Nanocorps anti-vcam-1
FR2986538B1 (fr) Utilisation du mir-199a-5p de ses cibles et/ou inhibiteurs pour le diagnostic, le pronostic et le traitement des pathologies fibroproliferatives
EP2588630A4 (en) MOLECULAR GENETIC APPROACH FOR THE TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG INDEPENDENCE
BR112013025197A2 (pt) métodos para tratar doença de alzheimer e para avaliar a eficáca de uma terapia destinada a tratar doença de alzheimer
EA201490548A1 (ru) Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости